Get caught up to speed on news from Wisconsin’s innovation community with these recent headlines:
—Madison-based Exact Sciences (NASDAQ: EXAS) said that Cologuard, the company’s stool-based DNA test for colorectal cancer, is slated to be included in the Centers for Medicare and Medicaid Services (CMS) Medicare Advantage Star Ratings. CMS publishes the Star Ratings each year to measure quality in Medicare Advantage health insurance programs. The proposal to include Cologuard in the Star Ratings marks “an important step toward it becoming a standard of care for colon cancer screening,” said Kevin Conroy, Exact’s chairman and CEO, in a prepared statement.
In October, Exact announced that Cologuard had been included in a group of quality measures for colorectal cancer screening, known as Healthcare Effectiveness Data and Information Set (HEDIS). The company said last week that Medicare Advantage Star Ratings are directly affected by HEDIS data, which among other things are used to assess Medicare plans. Read the full story here.